Contineum Therapeutics Inc (NASDAQ: CTNM) is -68.46% lower on its value in year-to-date trading and has touched a low of $3.85 and a high of $22.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CTNM stock was last observed hovering at around $4.38 in the last trading session, with the day’s gains setting it 0.24%.
Currently trading at $4.62, the stock is -20.90% and -31.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.14 million and changing 5.48% at the moment leaves the stock -67.36% off its SMA200. CTNM registered -70.29% loss for a year compared to 6-month loss of -71.90%. The firm has a 50-day simple moving average (SMA 50) of $6.7728 and a 200-day simple moving average (SMA200) of $14.15245.
The stock witnessed a -38.32% gain in the last 1 month and extending the period to 3 months gives it a -62.98%, and is 11.86% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.59% over the week and 10.75% over the month.
Contineum Therapeutics Inc (CTNM) has around 41 employees, a market worth around $119.53M and $0.00M in sales. Distance from 52-week low is 20.00% and -79.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-20.83%).
The EPS is expected to shrink by -3.52% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
91.0 institutions hold shares in Contineum Therapeutics Inc (CTNM), with institutional investors hold 88.73% of the company’s shares. The shares outstanding are 19.13M, and float is at 13.50M with Short Float at 5.11%. Institutions hold 82.57% of the Float.
The top institutional shareholder in the company is SUVRETTA CAPITAL MANAGEMENT, LLC with over 2.05 million shares valued at $36.16 million. The investor’s holdings represent 7.9824 of the CTNM Shares outstanding. As of 2024-06-30, the second largest holder is JOHNSON & JOHNSON with 1.98 million shares valued at $34.85 million to account for 7.6941 of the shares outstanding. The other top investors are PERCEPTIVE ADVISORS LLC which holds 1.57 million shares representing 6.0905 and valued at over $27.59 million, while VERSANT VENTURE MANAGEMENT, LLC holds 3.5694 of the shares totaling 0.92 million with a market value of $16.17 million.
Contineum Therapeutics Inc (CTNM) Insider Activity
The most recent transaction is an insider sale by Lorrain Daniel S., the company’s Chief Scientific Officer. SEC filings show that Lorrain Daniel S. sold 1,010 shares of the company’s common stock on Nov 25 ’24 at a price of $16.02 per share for a total of $16177.0. Following the sale, the insider now owns 0.17 million shares.
Contineum Therapeutics Inc disclosed in a document filed with the SEC on Nov 18 ’24 that Lorrain Daniel S. (Chief Scientific Officer) sold a total of 6,190 shares of the company’s common stock. The trade occurred on Nov 18 ’24 and was made at $16.38 per share for $0.1 million. Following the transaction, the insider now directly holds 0.17 million shares of the CTNM stock.
Still, SEC filings show that on Nov 18 ’24, DANIEL LORRAIN (Officer) Proposed Sale 26,370 shares at an average price of $17.21 for $0.45 million. The insider now directly holds shares of Contineum Therapeutics Inc (CTNM).
